Dr Reddy's, subsidiaries launch Bosutinib tablets 400 mg in US
This story was originally published at 13:46 IST on 13 June 2026
Register to read our real-time news.Informist, Saturday, Jun. 13, 2026
--Dr Reddy's, subsidiaries launch Bosutinib tablets 400 mg in US
MUMBAI – Dr. Reddy's Laboratories Ltd. and its subsidiaries Saturday announced the first-to-market launch of Bosutinib tablets 400 mg, a generic equivalent of Bosulif in the US, the company said in an exchange filing.
Bosutinib Tablets (400mg) was a first-to-file product and is eligible for 180 days of generic drug exclusivity for this strength in the US.
For the March quarter, Dr. Reddy's Laboratories reported consolidated net profit of INR 2.21 billion on revenues of INR 75.46 billion. Friday, its shares ended at INR 1,275.40 on the National Stock Exchange, down 0.1%. End
Reported by Meera Nair
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
